

Antibody	Immunogen	Protocol	Mouse strain	
GM37	FL human Alpha- synuclein fibrils Alternating with 1-60 alpha- synuclein 1-119 alpha- synuclein	Complete Freunds adjuvant and incomplete Freunds adjuvant	HCo17-Balb/c	
GM285	FL human alpha- synuclein monomer followed by fibrils or monomer	Complete Freunds adjuvant and incomplete Freunds adjuvant	HCo12-Balb/c	

Fig 1




Fig 2A




Fig 2B





Fig 2B (continued)




Fig 2B (continued)




Fig 2C




Fig 2C (continued)




Fig 2C (continued)




Fig 2C (continued)

10/46




Fig 2C (continued)

A





FIG 3

12/46

B**C**

Name	KA(1/M)	KD(nM)	Rmax	Chi2
hlgG1-6004-037 C106S	2.33E+08	4.29	61.1	0.96

Fig 3 (continued)







FIG 4

B**C**

Name	KA(1/M)	KD(nM)	Rmax	Chi2
hlgG1-6004-085	2.33E+08	4.30	56.3	0.77

Fig 4 (continued)





C)

Name	KA(1/M)	KD(nM)	Rmax	Chi2
hlgG1-9E4	2.58E+08	3.88	49.2	0.61

Fig 5 (continued)

FIG. 6. Amino acid sequence

↓
MDVFMKGLSKAKEGVVAAAEKTKQGVAAEAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVV
TGVTAQAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA
↑ ↑ ↑

Fig 6




Fig 7

MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAV
AQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEG**I**LEDMPVDPD**NEAY**EMPSEEGYQDYEPEA




Fig 8





Fig 9

**Fig 10**

A




Fig 11A




Fig 11B




Fig 12A




Fig 12B




Fig 12C

27/46





Fig 12C (continued)

Fig 12D

**Fig 13**




Fig 14

Figure 15




Fig 15




Fig 16




Fig 17




Fig 18





Fig 19

**Fig 20A**

37/46




Fig 20B

38/46




Fig 20C

39/46




Fig 20D




Fig 21

[illegible]

Product	Lot number	Concentration [#] (mg/ml)	Volume [#] (ml)	Yield [#] (mg)	Titre [†] (mg/L)
GM37 _wt	319-121115-01	2.11	6.0	12.6	31.6
GM37 _var1	319-121115-02	1.70	5.0	8.5	21.2
GM37 _var2	319-121115-03	2.57	5.8	14.9	37.2
GM37 _var3	319-121115-04	1.85	5.0	9.3	23.2

Fig 23

43/46




Fig 24

44/46



Sample	ka (1/Ms)	kd (1/s)	KD (nM)	Rmax (RU)	Chi ² (RU ²)	U-value
GM37_wt , batch 2	7,01E+05	1,92E-02	27	1,4	0,0022	3
GM37_wt, batch 1	5,28E+05	1,48E-02	28	1,5	0,0024	2
GM37_Variant 1	6,34E+05	1,37E-02	22	1,5	0,0022	2
GM37_Variant 2	4,15E+05	1,24E-02	30	1,4	0,0021	3
GM37_Variant 3	5,77E+05	2,28E-02	40	1,5	0,0016	2
Isotype control			NB	NB		

Fig 25




Fig 26




Fig 27